Table 4.
Specific drugs for the treatment of HFrEF and the importance of hyperkalaemia as the reason for not administering or reaching a target dose.
| Drugs | Number of Patients Receiving Treatment [n (%)] | Hyperkalaemia as a Cause of Contraindication or Intolerance [n/Number of Patients with Contraindication or Who Did Not Tolerate the Drug (%)] |
Patients Not Reaching Target Dose [n/Number Patients Receiving Drug (%)] |
Hyperkalaemia as a Cause of Not Reaching Target Dose [n/Number of Patients Who Do Not Reach the Target Dose (%)] |
|---|---|---|---|---|
| ACEi | 107 (18.9) | 3/72 (4.2) | 67/107 (62.6) | 2/67 (3.0) |
| ARBs | 64 (11.3) | 2/83 (2.4) | 46/64 (71.9) | 2/46 (4.3) |
| MRAs | 441 (78.5) | 24/69 (34.8) | 311/441 (70.5) | 39/311 (12.5) |
| ARNi | 361 (63.8) | 3/65 (4.6) | 225/361 (62.3) | 13/225 (5.8) |
| BBs | 525 (92.9) | N.A. | 335/525 (63.8) | N.A. |
Notes: ACEi, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; ARNi, angiotensin receptor-neprilysin inhibitors; BBs, beta-blockers; HFrEF, heart failure and reduced ejection fraction; MRAs, mineralocorticoid receptor antagonists; N.A., not applicable.